Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study
Giuseppe Lamberti(Dana-Farber Cancer Institute), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Saverio Cinieri(Ospedale A. Perrino), Donatella Giardina(Azienda Unita' Sanitaria Locale Di Modena), Francesca Mazzoni(Azienda Ospedaliero-Universitaria Careggi), Karim Rihawi(Azienda USL di Bologna), Michele Tognetto(University of Aberdeen), Matteo Brighenti(Azienda Ospedaliero-Universitaria Careggi), Ida Colantonio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Federica Bertolini, Marcello Tiseo(University of Parma), Elisa Andrini(University of Bologna), Luca Boni(Ospedale Policlinico San Martino), Andrea Bonetti(Italian Oncology Group of Clinical Research), Carlo Genova(Ospedale Policlinico San Martino), Alessandro Follador(Ospedale Santa Maria della Misericordia di Udine), Giulia Pasello(University of Padua), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 5
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931